CORRESP Filing
Inhibitor Therapeutics, Inc.
Date: July 22, 2025 · CIK: 0001042418 · Accession: 0001641172-25-020608
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-13467
Letter
Inhibitor Therapeutics, Inc.
W. Palmira Avenue
Suite
Tampa, FL 33629
VIA EDGAR
July 22, 2025
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
F Street, N.E.
Washington, D.C. 20549
Attention:
Joshua Gorsky Chris Edwards
Re: Inhibitor Therapeutics, Inc.
Form 10-K for the Year Ended December 31, 2024
Filed March 28, 2025
File No. 001-13467
Ladies and Gentlemen:
Inhibitor Therapeutics, Inc. (the " Company ," " we ," " our " or " us ") hereby transmits our response to the comment letter received from the staff (the " Staff ", " you " or " your ") of the U.S. Securities and Exchange Commission (the " Commission "), dated July 17, 2025, regarding the Form 10-K for the fiscal year ended December 31, 2024 (the " Form 10-K ") submitted to the Commission on.
For the Staff's convenience, we have repeated below the Staff's comment in bold and have followed each comment with the Registrants' response. In response to the Staff's comments, the Registrants are filing via Edgar a response letter.
Annual Report on Form 10-K
Item 1. Description of Business, page 3
1. We note your disclosure on page 3 that, on December 12, 2023, you entered into an Exclusive License Agreement with Johns Hopkins University. In future filings, please provide further details about the material terms of this agreement including, but not limited to, the aggregate amount that could be owed to Johns Hopkins University pursuant to the agreement, the aggregate milestone amounts to be paid, and the royalty range and term, as applicable.
Response : In response to the Staff's comment, the Company respectfully advises the Staff that it will revise the disclosure in future filings, initially in its Form 10-Q for the fiscal quarter ended June 30, 2025, to include the material terms of the agreement, including the aggregate milestone amounts to be paid, and the royalty range and term, as applicable, for the Exclusive License Agreement with Johns Hopkins University.
We thank the Staff in advance for its consideration of the foregoing. Should you have any questions, please do not hesitate to contact our legal counsel, Justin Grossman, Esq., of Ellenoff Grossman & Schole LLP, at (212) 370-1300.
Sincerely,
By:
/s/
James A. McNulty
Show Raw Text
CORRESP 1 filename1.htm Inhibitor Therapeutics, Inc. 3014 W. Palmira Avenue Suite 302 Tampa, FL 33629 VIA EDGAR July 22, 2025 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Joshua Gorsky Chris Edwards Re: Inhibitor Therapeutics, Inc. Form 10-K for the Year Ended December 31, 2024 Filed March 28, 2025 File No. 001-13467 Ladies and Gentlemen: Inhibitor Therapeutics, Inc. (the " Company ," " we ," " our " or " us ") hereby transmits our response to the comment letter received from the staff (the " Staff ", " you " or " your ") of the U.S. Securities and Exchange Commission (the " Commission "), dated July 17, 2025, regarding the Form 10-K for the fiscal year ended December 31, 2024 (the " Form 10-K ") submitted to the Commission on. For the Staff's convenience, we have repeated below the Staff's comment in bold and have followed each comment with the Registrants' response. In response to the Staff's comments, the Registrants are filing via Edgar a response letter. Annual Report on Form 10-K Item 1. Description of Business, page 3 1. We note your disclosure on page 3 that, on December 12, 2023, you entered into an Exclusive License Agreement with Johns Hopkins University. In future filings, please provide further details about the material terms of this agreement including, but not limited to, the aggregate amount that could be owed to Johns Hopkins University pursuant to the agreement, the aggregate milestone amounts to be paid, and the royalty range and term, as applicable. Response : In response to the Staff's comment, the Company respectfully advises the Staff that it will revise the disclosure in future filings, initially in its Form 10-Q for the fiscal quarter ended June 30, 2025, to include the material terms of the agreement, including the aggregate milestone amounts to be paid, and the royalty range and term, as applicable, for the Exclusive License Agreement with Johns Hopkins University. We thank the Staff in advance for its consideration of the foregoing. Should you have any questions, please do not hesitate to contact our legal counsel, Justin Grossman, Esq., of Ellenoff Grossman & Schole LLP, at (212) 370-1300. Sincerely, By: /s/ James A. McNulty Name: James A. McNulty Title: Chief Financial Officer cc: Ellenoff Grossman & Schole LLP